Application of Bispecific Therapy in Clinical Practice
Syed S. Ali, MD, and Noffar Bar, MD, share their practical experience with bispecific antibodies in the treatment of patients with multiple myeloma.
EP: 1.The ‘Golden Age’ of Daratumumab: Highlights From an Expert Panel on Multiple Myeloma
EP: 2.Triplet and Quadruplet Induction Regimen Options for Patients With Transplant-Eligible NDMM
EP: 3.Data Updates From GRIFFIN and MASTER in Transplant-Eligible NDMM
EP: 4.Exploring the GMMG-CONCEPT Study in Patients With Transplant-Eligible NDMM
EP: 5.Assessing and Treating Patients with High-Risk NDMM
EP: 6.Treatment Approaches in Patients With Transplant-Ineligible NDMM
EP: 7.Subset Analysis of the MAIA Study in the Frail Multiple Myeloma Population
EP: 8.Available Treatment Options for Patients With R/R MM
EP: 9.Updated Results of the MonumenTAL-1 Study in R/R MM
Now Viewing
EP: 10.Application of Bispecific Therapy in Clinical Practice
EP: 11.Discussing Bispecific Antibody Treatment With Patients With Multiple Myeloma
EP: 12.Comparing Bispecifics and CAR T-Cell Therapy for Patients With MM
EP: 13.Unmet Needs in the Treatment of Multiple Myeloma
EP: 14.Treatment of Multiple Myeloma: Q&A Session With Yale Cancer Center and Satellites
Recent Videos
Related Content
Administering CAR T-Cell Therapy and Bispecific Agents in Nursing Practice
Ishmael Applewhite, BSN, RN-BC, OCN;Leslie Bennett, MSN, RN;Kathy Mooney, MSN, RN, ACNS-BC, BMTCN®, OCN®
May 6th 2024Podcast
Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.
